2. Guidelines for the Clinical Management and Treatment of HIV-infected Adults in Europe (Version 10.0; November, 2019). European AIDS Clinical Society http://www.eacsociety.org

3. ВОЗ. Обновление рекомендаций по антиретровирусной терапии первой и второй линии. Женева, Швейцария, 2019 (WHO/CDS/HIV/19.15). Лицензия: CC BY-NC-SA 3.0 IGO. http://apps.who.int/iris

[WHO. Updating recommendations for first-and second-line antiretroviral therapy]. Geneva, Switzerland, 2019 (WHO/CDS/HIV/19.15). License: CC BY-NC-SA 3.0 IGO. http://apps.who.int/iris

4. Koethe J.R., Jenkins C.A., Lau B., Shepherd B.E., Justice A.C., Tate J.P. et al. Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada. AIDS Research and Human Retroviruses 2016; 32(1): 55–8. DOI: 10.1089/aid.2015.0147

5. Sax P.E., Erlandson K.M., Lake J.E., McComsey G.A., Orkin C., Esser S. et al. Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. Clin. Infect. Dis. 2019; XX(XX): 1–11. DOI: 10.1093/cid/ciz999

6. Hill A., McCann K.M., Pilkington V., Moorhouse M.A., Sokhela S., Serenata C.M. et al. Risks of metabolic syndrome, diabetes, and cardiovascular disease in advance trial. Conference on Retroviruses and Opportunistic Infections (CROI). USA, Boston, 8–11 March 2020. Abstract 81, p. 28. www.croiconference.org

7. McCann K., Moorhouse M., Sokhela S., Venter W.D.F., Serenata C., Qavi A. et al. The ADVANCE clinical trial: changes from baseline to week 96 in DXA-assessed body composition in TAF/FTC + DTG compared to TDF/FTC + DTG, and TDF/FTC/EFV. EACS 2019. HIV Medicine 2019; 20(Suppl. 9). Abstract book, Abstract PS3/3, p. 8.

8. Rebeiro P.F., Jenkins C., Bian A., Lake J.E., Bourgi K., Althoff .K.N. et al. Diabetes, weight gain, and integrase inhibitor use in North American HIV+ persons. Conference on Retroviruses and Opportunistic Infections (CROI). USA, Boston, 8–11 March 2020. Abstract 680, p. 248. www.croiconference.org

9. Burdet C., Peytavin G., Le M., Landman R., Bachelet D., Katlama C. et al. Drug concentrations and body weight gain in plwh switched to 3TC & Dolutegravir (DTG). Conference on Retroviruses and Opportunistic Infections (CROI). USA, Boston, 8–11 March 2020. Abstract 677, p. 247. www.croiconference.org

10. Orkin C., Elion R., Thompson M., Rockstroh J., Xu Z.J., Martin E.A. Effect of doravirine on body weight and body mass index in treatment naıve adults with HIV-1. EACS 2019. HIV Medicine 2019; 20(Suppl. 9). Abstract book. Abstract PS3/2, p. 7–8.